Literature DB >> 21070080

Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue.

Simeng Suy1, Eric Oermann, Heather Hanscom, Sue Lei, Saloomeh Vahdat, Xia Yu, Hyeon U Park, Viola Chen, Brian T Collins, Kevin McGeagh, Nancy Dawson, Reena Jha, Norio Azumi, Anatoly Dritschilo, John Lynch, Sean P Collins.   

Abstract

We describe the first histopathologic analysis of prostatic tissue following hypofractionated robotic radiation therapy. A 66 year-old man presented with stage II, low risk adenocarcinoma of the prostate and underwent elective conformal hypofractionated radiation therapy. His pretreatment evaluation revealed T1c adenocarcinoma, Gleason's grade 3 + 3 = 6 and a prostate specific antigen (PSA) level of 4.87 ng/ml. Hypofractionated radiation therapy (37.5 Gy in five daily fractions of 7.5 Gy) was completed on an Internal Review Board approved protocol. One year later, he developed progressive urinary retention. Transurethral prostatic resection was performed to alleviate obstructive symptoms. Bilobar hypertrophy was observed without evidence of stricture. Histolopathologic analyses of resected prostate tissues revealed changes consistent with radiation treatment, including cellular changes, inflammation, glandular atrophy and hyperplasia. There was no evidence of residual cancer, fibrosis or necrosis. The patient's postoperative course was uneventful with post-treatment PSA of 0.5 ng/ml and residual grade 1 stress incontinence.

Entities:  

Mesh:

Year:  2010        PMID: 21070080     DOI: 10.1177/153303461000900606

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  3 in total

1.  The role of TRAIL in fatigue induced by repeated stress from radiotherapy.

Authors:  Li Rebekah Feng; Simeng Suy; Sean P Collins; Leorey N Saligan
Journal:  J Psychiatr Res       Date:  2017-03-20       Impact factor: 4.791

2.  Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.

Authors:  Jennifer A Woo; Leonard N Chen; Aditi Bhagat; Eric K Oermann; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2014-05-26       Impact factor: 6.244

3.  Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer.

Authors:  Li Rebekah Feng; Simeng Suy; Sean P Collins; Jonathan W Lischalk; Berwin Yuan; Leorey N Saligan
Journal:  Curr Urol       Date:  2018-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.